Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice

Exposure to high concentrations of hydrochloric acid (HCl) can lead to severe acute and chronic lung injury. In the aftermath of accidental spills, victims may be treated for the acute symptoms, but the chronic injury is often overlooked. We have developed a mouse model of acute and chronic lung inj...

Full description

Saved in:
Bibliographic Details
Main Authors: Pavel A. Solopov (Author), Ruben Manuel Luciano Colunga Biancatelli (Author), Christiana Dimitropolou (Author), Tierney Day (Author), John D. Catravas (Author)
Format: Book
Published: Frontiers Media S.A., 2022-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_6fd9367f53c24f86b43a951f9b9c6760
042 |a dc 
100 1 0 |a Pavel A. Solopov  |e author 
700 1 0 |a Ruben Manuel Luciano Colunga Biancatelli  |e author 
700 1 0 |a Christiana Dimitropolou  |e author 
700 1 0 |a Tierney Day  |e author 
700 1 0 |a John D. Catravas  |e author 
700 1 0 |a John D. Catravas  |e author 
245 0 0 |a Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice 
260 |b Frontiers Media S.A.,   |c 2022-11-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.1034464 
520 |a Exposure to high concentrations of hydrochloric acid (HCl) can lead to severe acute and chronic lung injury. In the aftermath of accidental spills, victims may be treated for the acute symptoms, but the chronic injury is often overlooked. We have developed a mouse model of acute and chronic lung injury, in which the peak of acute lung injury occurs on the day 4 after HCl exposure. We have also demonstrated that HSP90 inhibitors are effective antidotes when administered starting 24 h after HCl. In this study we examined the hypothesis that the novel oral HSP90 inhibitor TAS-116 can effectively ameliorate HCl-induced lung injury even when treatment starts at the peak of the acute injury, as late as 96 h after HCl. C57BI/6J mice were intratracheally instilled with 0.1N HCl. After 24 or 96 h, TAS-116 treatment began (3.5, 7 or 14 mg/kg, 5 times per week, p. o.) for either 2,3 or 4 or weeks. TAS-116 moderated the HCl-induced alveolar inflammation, as reflected in the reduction of white blood cells and total protein content in bronchoalveolar lavage fluid (BALF), overexpression of NLRP3 inflammasome, and inhibited the activation of pro-fibrotic pathways. Furthermore, TAS-116 normalized lung mechanics and decreased the deposition of extracellular matrix proteins in the lungs of mice exposed to HCl. Delayed and shortened treatment with TAS-116, successfully blocked the adverse chronic effects associated with acute exposure to HCl. 
546 |a EN 
690 |a idiopathic pulmonarry fibrosis 
690 |a Hsp90 inhibitior 
690 |a TAS-116 
690 |a mice 
690 |a hydrochloric acid 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.1034464/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/6fd9367f53c24f86b43a951f9b9c6760  |z Connect to this object online.